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Background and the aim of the study: The objective of the present study was to formulate and optimize
nanoparticles (NPs) of sildenafil-loaded poly (lactic-co-glycolic acid) (PLGA) by double emulsion solvent evaporation
(DESE) method. The relationship between design factors and experimental data was evaluated using response
surface methodology.
Method: A Box-Behnken design was made considering the mass ratio of drug to polymer (D/P), the volumetric
proportion of the water to oil phase (W/O) and the concentration of polyvinyl alcohol (PVA) as the independent
agents. PLGA-NPs were successfully prepared and the size (nm), entrapment efficiency (EE), drug loading (DL) and
cumulative release of drug from NPs post 1 and 8 hrs were assessed as the responses.
Results: The NPs were prepared in a spherical shape and the sizes range of 240 to 316 nm. The polydispersity
index of size was lower than 0.5 and the EE (%) and DL (%) varied between 14-62% and 2-6%, respectively. The
optimized formulation with a desirability factor of 0.9 was selected and characterized. This formulation demonstrated
the particle size of 270 nm, EE of 55%, DL of 3.9% and cumulative drug release of 79% after 12 hrs. In vitro release
studies showed a burst release at the initial stage followed by a sustained release of sildenafil from NPs up to 12 hrs.
The release kinetic of the optimized formulation was fitted to Higuchi model.
Conclusions: Sildenafil citrate NPs with small particle size, lipophilic feature, high entrapment efficiency and good
loading capacity is produced by this method. Characterization of optimum formulation, provided by an evaluation of
experimental data, showed no significant difference between calculated and measured data.
Keywords: Sildenafil citrate, Nanoparticle, Optimization, Box-Behnken, Double emulsionBackground
Sildenafil is a selective inhibitor of phosphodiesterase
enzyme type 5 (PDE-5) that effectively inactivates cyclic
guanosine monophosphate (cGMP) and enhances the
effect of nitric oxide [1]. This drug was primarily pre-
scribed for angina pectoris and now is widely used for the
treatment of erectile dysfunction [2]. Recently, PDE-5
inhibitors have been proposed to protect the endothelial
function in human by selectively improving local blood
flow [3]. Moreover, other complications like wound* Correspondence: vatanara@tums.ac.ir
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distribution, and reproduction in any mediumhealing, diabetic gastropathy [4], Reynaud’s phenomenon,
respiratory disorders with ventilation/perfusion mismatch,
congestive cardiac failure, hypertension and stroke have
been widely studied with the hope that PDE-5 inhibitors
can serve as novel promising treatment in such condi-
tions. In addition, the selective and potent vasodilatory
and antiproliferative effects of sildenafil on pulmonary
vascular smooth muscle cells emphasize the importance
of this drug in control of pulmonary artery pressure [4-6].
When sildenafil citrate (SC) is given orally, its bioavaila-
bility is relatively low (approximately 40%) in healthy sub-
jects [7] because of the first pass metabolism. In addition,
it exhibits a very short physiological half-life (about
3–4 hrs). Therefore repeated doses are required to sustaintral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Factors and factor levels studied in a Box–Behnken
experimental design
Levels
Factors Low (−1) Medium (0) High (1)
X1 D/P 0.05 0.13 0.2
X2 W/O 0.25 0.38 0.5
X3 %PVA 0.1 0.55 1
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as headache, flushing, dyspepsia and epistaxis [9].
Specially designed dosage forms that sustain levels of
drug in the therapeutic window or local delivery of this
drug into the site of action can be thus helpful [8,10].
Some published patents have reported that application of
nano sized SC powder in formulation, shows faster onset
of action, higher bioavailability and absorption than con-
ventional dosage form [11-13]. Thus, nanoparticles (NPs)
might improve the efficacy; reduce side effects and dosage
of therapeutic agents [14]. Generally, nanocarrier systems
provide advantages over conventional drug delivery sys-
tems such as protection of the entrapped drug from
enzymatic destruction, sustained drug release, reduction
of daily drug doses and side effects and cell targeting
[15]. Consequently, biodegradable polymeric NPs have
engrossed remarkable consideration as potential drug
delivery devices in view of their applications in the con-
trolled release of drugs [16]. poly(lactic-co-glycolic acid)
(PLGA) is the most successfully used available biodegra-
dable polymer due to its long clinical experience, desirable
degradation characteristics and possibilities for sustained
drug delivery [17]. This polymer is widely used in the pro-
duction of NPs [18]. PLGA consists two endogenous
monomers that are easily metabolized via the Krebs cycle
and therefore, negligible systemic toxicity is associated
with the use of PLGA for drug delivery [19]. Also, study of
in vitro and in vivo cytotoxicity of PLGA nanoparticles
highlighted the safety of biodegradable PLGA nanopar-
ticles [20,21]. Selection of a particular method for pre-
paration of NPs is usually determined by the solubility
properties of the drug [22]. Double Emulsion Solvent
Evaporation (DESE) technique is an effective method for
encapsulation of hydrophilic compounds [23] and thus we
selected this method to fabricate NPs, because of the polar
properties of SC [24]. There are several variables in the
DESE process that can affect the properties of the product.
Response surface methodology (RSM) is a statistical
method employed for the modeling and analysis of pro-
blems in which a response of concern is influenced by
several variables and the goal is to optimize this response
[25]. Application of such optimizing technique may be
an efficient and economical method to gain the essential
information and thus to understand the relationship
between controllable independent variables and depen-




PLGA, Resomer® RG503H, was acquired from Boehringer
Ingelheim (Germany). Polyvinyl alcohol (PVA) (87–90% hy-
drolysis degree and molecular mass 30,000-70,000 g/mol)
was purchased from Sigma Chemical Co. (USA). SC waspurchased from Selleck Chemicals (USA). The organic
solvents were supplied by Duksan (Korea).
Preparation of SC-loaded Nanoparticles
At the first, the drug was dissolved in warm distilled water
(3 mg/ml) and emulsified in methylene chloride con-
taining different amounts of PLGA. The emulsification
was carried out using a probe sonicator set (Hielscher,
Germany) at 80% of the energy output for 3 min. Then,
the primary emulsion was added to 20 ml of double dis-
tilled water containing PVA and homogenized for 3 min
in 20,000 rpm (IKA, Germany). Methylene chloride was
eliminated by evaporation under reduced pressure using a
rotary evaporator (Buchi, Switzerland). NPs were reco-
vered by ultracentrifugation (Beckman Instruments, USA)
at 100,000 g for 60 min at 25°C.
Experimental design
The effects of formulation variables on the NPs character-
istics and optimization procedure were examined by
employing a Box-Behnken design. The design and statis-
tical analysis were performed by Design-Expert® V8 (DX8)
Software for design of experiments (DOE). Experimental
factors and factor levels were determined in preliminary
studies. Studied responses which evaluated in this investi-
gation, were the mass ratio of drug to PLGA (X1), the
volumetric ratio of water to solvent in primary emulsion
(X2) and the concentration of PVA (X3) that classified to
low, medium, and high values for the chosen variables as
are described in Table 1. The evaluated studied responses
were size (nm), entrapment efficiency (EE), drug loading
(DL) and drug release in 1 hr and 8 hrs. The Box-Behnken
design and observational data are shown in Table 2.




In which Y is the measured response associated with
each factor level combination; A0 is an intercept; A1-A9




2 are quadratic effects, X1X2 +
X2X3 + X1X3 are interaction between variables and E is
the error term [27].
Table 2 Run parameters and responses for three-level three-factorial Box–Behnken experimental design
Runs order D/P W/O PVA (%) Size (nm) EE (%) DL (%) Drug release in 1 hr Drug release in 8 hrs
1 1 0 −1 291 35 6.3 70 72
2 0 0 0 241 43 5.3 62 68
3 −1 0 1 316 51 3.2 30 39
4 1 0 1 259 28 5.1 79 79
5 0 −1 −1 259 26 3.1 75 80
6 0 0 0 279 47 5.8 49 50
7 0 −1 1 260 16 2 80 92
8 0 1 −1 304 32 4 51 59
9 0 1 1 311 32 4.1 36 43
10 −1 1 0 301 49 2.4 54 62
11 1 −1 0 246 14 2.5 92 93
12 1 1 0 261 26 4.8 79 81
13 0 0 0 268 45 5.5 77 86
14 −1 0 −1 303 62 3 29 40
15 0 0 0 260 45 5.6 49 65
16 −1 −1 0 278 41 2 61 75
17 0 0 0 240 46 5.6 50 64
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Particle size
Mean hydrodynamic size (called z-average) and polydis-
persity index of the NPs were measured by photon cor-
relation spectroscopy (Malvern, UK) at 25C. All the
samples were diluted with double distilled water to create
a suitable obscuration before analysis.
Determination of entrapped SC
The supernatant part of the centrifuged NP sample was
carefully removed and examined to determine the amount
of non-encapsulated drug. The precipitant was lyophilized,
weighted, and then dissolved in a mixture of 3:2 of chloro-
form (a common solvent for PLGA) and water (a solvent
for SC) by sonicating for one hour. Then, the undissolved
fraction was removed by centrifugation. After that, a sam-
ple was taken from the aqueous phase to determine the
amount of encapsulated SC. The drug incorporation effi-
ciency was defined by the following formulas:
DL %ð Þ ¼ Massof sildenafil inNPs
Themassof NPsrecovered
100
EE %ð Þ ¼ Massof encapsulatedsildenafil
Massof the total sildenafil
100
A reverse phase chromatography method was used for
evaluation of SC using isocratic HPLC system (Waters,
USA) and NucleoDur (5 μm, 25 cm) C18 column. The
mobile phase consisted of acetonitrile and water (35:65,
pH 4.0) at a flow rate of 1 ml/min with UV detection at
291 nm. The retention time was 5.6 min.Differential scanning calorimetry (DSC)
A differential scanning calorimeter (Mettler Toledo,
Switzerland) was used to evaluate the thermal behavior of
all materials used in the NP formulations. The equipment
was calibrated using indium. The samples (8 mg) were
heated ranging 5–280°C at a scanning rate of 10°C/min in
aluminum pans under nitrogen gas.
Scanning electron microscopy (SEM)
The surface morphology of NPs was assessed by a scanning
electron microscope (Mira Tescan, Czech Republic). The
Nanoparticles were spread on a stub and dried at 25°C and
then spattered with gold using a sputter coater (BAL-TEC,
Switzerland).
In vitro drug release studies
To predict the optimal formulation of NPs, the drug re-
lease of each formulation was studied in phosphate buffer
(PBS) at pH 7.4 as dissolution medium. Briefly, 10 mg of
each lyophilized NP formulation was dispersed in a screw-
capped glass vial (50 ml) containing 40 ml of medium by
shaking at 200 rpm and 37 ± 0.5°C in shaker incubator
(LABOTEC, Germany). At predetermined time intervals
(0, 0.5, 1, 2, 4, 8, 10, 12, 24 hrs) 1 ml of the dispersion was
taken away and replaced with 1 ml of fresh PBS. The sam-
ple was centrifuged (Eppendorf, Germany) at 14,000 g for
30 min, and the supernatant was analyzed. All of the ex-
periments were done in triplicate.
The release kinetics from optimal NPs was fitted on
zero order, first order, Higuchi model, Korsmeyer–Peppas
model and Hixson–Crowell model [28].
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NPs were successfully prepared by DESE method. The
effects of formulation variables on the NP properties were
evaluated and finally optimal NPs were proposed by
design expert software. The characteristics of this formu-
lation were compared to predicted values. In addition, re-
lease profile and release kinetics from optimal NPs were
studied.
Particle size
SC loaded NPs sizes varied between 240 to 316 nm. For-
mulations displayed polydispersity index (PDI) of <0.5
which showed the narrow NP size distribution.
Analysis of data from ANOVA test exhibited that D/P
and W/O ratios had significant effects on particle size
(p < 0.05). Briefly, decrease in the D/P and increasing the
W/O ratios resulted in the production of larger particles
(Figure 1).
In size response, the reduced model showed better ad-
justed correlation coefficients than the primary model
(0.72 > 0.62) with an F value of 8 (p < 0.05), which clearly
indicated that the particle size and some variables were
related. The reduced model for predicting size is pre-
sented in equation 1.
Particle size ¼ þ258:68–17:63X1 þ 16:75X2–1:38X3
þ11:46X12 þ 23:46X32–11:25X1 X3
ð1Þ
The minimum particle size of 240 nm was achieved by
operating the experiment at the midpoint of each inde-
pendent variable. Analysis of independent factors showed
that D/P and W/O ratios had effective impacts on particle
size. There was no significant interaction between the
studied factors.Figure 1 Surface plot showing the effect of different variables on parDetermination of entrapped SC
The EE of NPs in different formulations is represented
in Table 2. Data analysis of this response proved the
significant effect of all independent variables (p < 0.05)
and an interaction between W/O ratio and the amount
of PVA (p < 0.05). The quadratic model of Entrapment
Efficiency followed equation 2.
EE ¼ þ 45:20 ‐ 12:50X1 þ 5:25X2 ‐ 3:50X3
þ 2:40X12 ‐ 15:10X22 ‐ 3:60X32
þ 1:00X1X2 þ 1:00X1X3
þ 2:50X2X3 ð2Þ
Surface plots indicated that higher EE occurred in for-
mulation with a W/O ratio about 0.38 and D/P ratios bet-
ween 0.05-0.09. Also, PVA concentration was less effective
than two other variables (Figure 2). The predictive model
for DL is given in equation 3:
DL ¼ þ5:56þ 1:01X1 þ 0:71X2‐0:25X3  0:77X12
1:87X22–0:39X32 þ 0:48X1 X2 ‐ 0:35X1 X3
þ0:30X2X3
ð3Þ
DL in NPs ranged between 2% and 6.3% (Figure 3);
where, analysis of data by ANOVA showed that the D/P
Ratio with an F value of 71.36 (p < 0.05) had the most
important impact on DL and W/O ratios had a significant
effect on this response (p < 0.05). Comparison of different
formulations and surface plots revealed that formulations
with the highest DL had the maximum D/P ratio of 0.2
and a W/O ratio of approximately 0.38.
In vitro drug release studies
To develop a formulation with acceptable release profile,
drug release of each formulation was studied. Data ofticle size of SC nanoparticles.
Figure 2 Three dimensional surface plots showing the effect of different variables on the %Entrapment Efficiency (EE) of
SC nanoparticles.
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ered as a marker of burst effect and the amount of drug
releasing in 8 hrs showed retardation efficiency over the
time. Analysis of the data demonstrated that W/O and
D/P ratios had significant influence on release profiles.
For predicting the release in 1 and 8 hrs, the linear
model fitted as an effective one with data (p < 0.05)
(equations 4–5).
%Release 1 hr ¼ þ60:18þ 18:25X1
 11:00X2 þ 0:000X3 ð4Þ
%Release 8 hrs ¼ þ67:53þ 13:63X1
 11:87X2 þ 0:25X3 ð5Þ
Data analysis showed that the D/P ratios with F values
of 17.08 and 9.10 (p < 0.05) were the most important fac-
tors on the release of SC from NPs during 1 and 8 hrs,
respectively (Figure 4). When the D/P ratio was mini-
mized and W/O ratio was about 0.38, the formulation
had the least burst release. On the other hand, thisFigure 3 Three dimensional surface plots showing the effect of differformulation could provide sustained release profile over
the time.
Optimization
After confirming the polynomial equations relating the
response and independent factors, in consequence of
acceptable size of all formulations, the optimization
model was constructed by combining the DL, EE and
drug release in 1 hr responses. Optimization was per-
formed by using a desirability function to obtain the
levels of X1, X2 and X3, which maximized EE, while
minimizing drug release in 1 hr and targeting DL at 4%.
Coefficients with p-value < 0.05 had a significant effect
on the prediction efficacy of the model for the measured
responses. Simultaneously, the formulation with W/O
about 0.40, D/P of 0.06 and PVA about 0.50 conformed
higher desirability. This formulation prepared and eva-
luated. Predicted and actual amounts of responses are
compared and shown in Table 3. As seen in Table 3,
excluding release in 1 h, the amount of responses for
optimized formulation have lower than 10% difference
with the predicted amount of Box-behnken design.ent variables on the %drug loading of SC nanoparticles.
Figure 4 Three dimensional surface plots showing the effect of different variables on the release of drug from SC nanoparticles during
1 hr and 8 hrs.
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Thermal analysis is a supportive tool for determining the
dispersion of the drug in polymeric materials. DSC ther-
mograms of the pure drug, PVA, PLGA and SC-NPs are
represented in Figure 5. The pure drug showed high endo-
thermic peak indication of its melting peak at ∼ 200°C
which was absent in NPs.
Scanning electron microscopy (SEM)
SEM micrographs showed that uniform PLGA NPs were
successfully prepared by using the DESE method. As
shown in Figure 6, the PLGA nanoparticles were in
spherical shapes and a smooth surface.
Release kinetics of optimal nanoparticles
Profile of release from optimal NPs is presented in
Figure 7. In vitro drug release profiles of SLD from opti-
mal PLGA NPs showed that the cumulative percentage of
drug release was about 79% of drug content of the for-
mulation in 12 hrs. The results support a burst release in
the first one hour that followed by a sustained release over
12 hrs.
Release kinetics from the optimum formulation of NPs
was compared to different kinetic models which showed
that the best model fitted with data is the Higuchian
equation (R2: 0.95). This model explains the release of
drug from an insoluble matrix time-dependently based
on Fickian diffusion [29]. The release constant was com-
puted from the slope of the suitable plots, and the re-
gression coefficient was determined (Table 4). The plots
and regression coefficient proved that after HiguchianTable 3 Comparison of actual and predicted properties of op
Size (nm) EE (%) D
Predicted amount 270 58.9
Actual amount 250 55
Error (%) 7.4 6.6model, the best linearity followed by first-order kinetic
(R2: 0.91). The first order kinetics model can be des-
cribed the drug dissolution of water-soluble drugs in
porous matrices [30].
Discussion
Although the most applied method for encapsulation of
hydrophilic drugs is DESE method, the low EE is usually
a major problem. Experimental design methodology is
an economic approach for extracting the maximum use-
ful information from data. Applying this technique re-
duces the costs of experiments by saving time, materials
and energy. Of course, optimization of NPs formulation
is a complex procedure, which involves considering vari-
ous parameters and their interactions. Due to increasing
use of sildenafil in the treatment of pulmonary diseases
and new indications proposed for this drug, preparation
of optimum loaded NPs that release drug over the time
can be potentially beneficial in the treatment of different
pathological conditions.
Particle size and size distribution are important physico-
chemical properties that determine both uptake and bio-
logical fate of the particulate systems [31]. In the results,
important effects of D/P and W/O ratios on size of NPs
were confirmed. Production of NPs with higher polymer
concentrations resulted in the formation of larger parti-
cles. In this manner, changing the diffusion rate of organic
solvent through the interface could be proposed as a fun-
damental mechanism. In fact, increasing the amount of
polymer or decreasing the volume of organic phase can
potentially hinder the diffusion of solvent moleculestimized NPs




Figure 5 DSC thermogram of PLGA, PVA, Sildenafil citrate and Sildenafil-nanoparticles.
Figure 6 SEM micrograph showing the morphology of optimized PLGA-Sildenafil nanoparticles.
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Figure 7 Profile of drug release from optimized SC nanoparticles.
Table 4 Results of model fitting for optimized Sildenafil
NPs
Models Slope R2 Intercept
Zero order 0.002 0.772 0
First order −0.106 0.925 4.496
Higuchi 21.44 0.950 0
Korsmayer-Peppas 0.51 0.860 3.044
Hixon-Crowell 0.187 0.656 2.264
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larger particles can be on account of two main factors:
(a) the number of polymer chains per volume unit of sol-
vent and (b) the viscosity of the solution [33]. As a result
of applying a greater number of the polymeric chains per
volume unit of solvent, diffusion of solvent into the aque-
ous phase becomes hard and causes the formation of
aggregated and larger NPs, which is in agreement with
previous reports [22,34]. On the other hand, it is more dif-
ficult for the viscous polymer solution to be broken up
into smaller droplets during the formation of a second
emulsion [35]. In this model, particle size reached to the
minimum point when D/P and W/O ratios were about
0.13 and 0.36. Data analysis defined no significant effect of
various PVA concentrations and this factor showed the
minor influence on the particle size in this study. Of
course, the presence of PVA as a surfactant is necessary to
form stabilized NPs.
As mentioned in DESE method, the low EE of small
and hydrophilic drug molecules into the polymer is an
important challenge [36]. The water soluble nature of
SC may be the cause of lower EE in higher D/P or W/O
ratios. The higher EE values gained by the higher poly-
mer contents can be explicated by the better coverage of
drug molecules within the polymeric matrix [37]. In
addition the initial amount of dissolved drug in the inner
phase showed a great influence on EE. As the difference
of drug concentrations between internal and external
aqueous phase increases, the drug diffuses faster to the
bulk aqueous phase during particle formation. In other
words, higher DL values resulted in lower encapsulation
efficiencies because of rapid partitioning of the drug be-
tween phases. So it can be claimed that DL and EE are
strongly related responses [22,38]. In the formulations
that the only changed parameter was W/O ratio, it
seems that this factor had a dual effect. Although de-
creasing this ratio resulted in more efficiently covered
aqueous droplets during first emulsion preparation, this
larger amount of organic phase required much moretime to evaporate [38]. So the drug molecules had greater
opportunity to escape from the inner to outer phase in
formulations with higher W/O ratios (>midpoint). While
the aqueous volume was kept constant, the enhanced vis-
cosity of the polymer solution led to the formation of
larger polymer/solvent droplets. Consequently, slower so-
lidification of larger particles allowed more drug diffusion
to the external phase, which again resulted in the lower
entrapment of the drug into the NPs [39]. Moreover,
employing higher concentrations of stabilizer in the exter-
nal aqueous phase induced higher EE values.
The endothermic peak of SC disappeared in the ther-
mogram of optimized drug loaded NPs, which indicated
absence of crystalline drug in the NPs. So, it can be
assumed that encapsulated drug was in an amorphous
state or a molecular dispersion throughout the polymer
matrix after fabrication of NPs [40].
SEM micrographs showed smooth surface and sphe-
rical shape of SC-NPs which can be explained by stabi-
lity of primary emulsion that the polymer had adequate
time to form the condense matrix around the drug mo-
lecules before particle formation [41].
All formulations were subjects of in vitro release studies.
The release profiles exhibited an initial burst release du-
ring the first hour, followed by a sustained release pattern
over 12 hrs. Surface response plots showed the influence
of D/P and W/O ratios on drug release from NPs. The ini-
tial burst release was related to the degree of DL, where
the minor burst effects were observed in lower DL values.
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cules might adsorb onto the surface of NPs, which con-
tribute to the greater initial release. Actually during the
first hour of release study, the large concentration gradient
of the drug serves as the driving force for the diffusion.
But during the next hours not only this gradient decreases
but also it takes more time for SC molecules to diffuse via
a path constructed from a series of interconnected pores
and channels within the polymeric matrix. It is supposed
that in formulations with lower polymer concentrations,
the internal water droplets have a greater tendency to co-
alescence and thus more likely to make larger pores and
less tortuous network. However, when the higher polymer
concentrations are applied, a tighter structure is formed as
a result of faster droplet coagulation during second emul-
sion formation and subsequent polymeric chain entangle-
ment. In another research published recently on the
formation of sildenafil-NPs, the sildenafil was incorpo-
rated as its water insoluble base into the PLGA-NPs by
means of solvent evaporation method, whereas the most
of the entrapped drug released during the first 90 min
[42]. Fortunately, in the present study, the release profile
of sildenafil citrate as a hydrophilic salt with better bio-
availability [1], improved up to 12 hrs.
Conclusion
Comparing the actual and predicted responses indicated
that surface response methodology is suitable to make
optimization of SC NPs to produce a biphasic release pat-
tern. These NPs can be utilized in the form of tablets or
processed in the presence of inhalable sugars to form a
dry powder for inhalation purposes. Further in vivo stu-
dies of SC NPs are recommended to determine whether
oral, topical, transdermal and respiratory efficacies are
created.
Although, providing SC in the form PLGA nanoparticles
brings some advantages such as improvement in reaching
many organs, tissues, and cells, the increased entrance
into cells might fundamentally rises the chance of toxic
effects. It is emphasized that changed size and surface area
of the present nano form of sildenafil makes it prone to
interact with various cellular components in various tis-
sues. Therefore, future studies to collect the relationships
between structure-size-efficacy-toxicity of the present
nano form of sildenafil with special regard to portal of
entry and target organ is crucial [43]. Additionally it
would be nice to prove the safety of the new nano form of
sildenafil in an appropriate biological system specially if
the expectation is to use the new form of sildenafil for
longer duration of time rather than its present single-dose
indication in erectile dysfunction [44].Competing interests
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